Emergent Technologies, Xencor deal

Emergent Technologies’ Receptor Logic company granted Xencor exclusive, worldwide rights to use a T cell receptor mimic mAb against cancer/testis antigen 1B ( CTAG1B; NY-ESO-1) to treat cancer. Xenco...